Characterization of ryanodine receptor-mediated calcium release in human B cells: Relevance to diagnostic testing for malignant hyperthermia

Anesthesiology

Volumn 104, Issue 6, 2006, Pages 1191-1201

  McKinney, Leslie C ^a,c   Butler, Thomas ^b   Mullen, Shawn P ^b   Klein, Michael G ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZA CYCLIC ADENOSINE DIPHOSPHATE RIBOSE; ADENOSINE DERIVATIVE; AZUMOLENE; CAFFEINE; CALCIUM ION; CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; CHLOROCRESOL; FURA 2; HALOTHANE; PROCAINE; RYANODINE; RYANODINE RECEPTOR; THAPSIGARGIN; UNCLASSIFIED DRUG; XESTOSPONGIN C;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CALCIUM CELL LEVEL; CALCIUM DEPLETION; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL LINE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE PREDISPOSITION; FLUOROMETRY; GENE MUTATION; HUMAN; HUMAN CELL; MALIGNANT HYPERTHERMIA; MITOCHONDRION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; REPRODUCIBILITY; SWINE;

ANIMALS; B-LYMPHOCYTES; CAFFEINE; CALCIUM; CARBONYL CYANIDE P-TRIFLUOROMETHOXYPHENYLHYDRAZONE; CELLS, CULTURED; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; MALIGNANT HYPERTHERMIA; OXAZOLES; RYANODINE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SWINE;

EID: 33744956995     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/00000542-200606000-00014     Document Type: Article

References (55)

1. Brandt A, Schleithoff L, Jurkat-Rott K, Klingler W, Baur C, Lehmann-Horn F: Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: Novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 1999; 8:2055-62
2. Sambuughin N, Holley H, Muldoon S, Brandom BW, de Bantel AM, Tobin JR, Nelson TE, Goldfarb LG: Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population. ANESTHESIOLOGY 2005; 102:515-21
3. Sei Y, Sambuughin N, Davis EJ, Sachs D, Cuenca PB, Brandom BW, Tautz T, Rosenberg H, Nelson TE, Muldoon S: Malignant hyperthermia in North America: Genetic screening of the three hot spots in the type I ryanodine receptor gene. ANESTHESIOLOGY 2004; 101:824-30
4. Brini M: Ryanodine receptor defects in muscle genetic diseases. Biochim Biophys Res Comm 2004; 322:1245-55
5. Ginz HF, Girard T, Censier K, Urwyler A: Similar susceptibility to halothane, caffeine, and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia. Eur J Anaesthesiol 2004; 21:151-7
6. Baur CP, Bellon L, Felleiter P, Fiege M, Fricker R, Glahn K, Heffron JJ, Herrmann-Frank A, Jurkat-Rott K, Klingler W, Lehane M, Ording H, Tegazzin V, Wappler F, Georgieff M, Lehmann-Horn F: A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility. Anesth Analg 2000; 90:200-5
7. Wappler F, Anetseder M, Baur CP, Censier K, Doetsch S, Felleiter P, Fiege M, Fricker R, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Hopkins PM, Klinger W, Lehmann-Horn F, Nivoche Y, Tegazzin V, Urwyler A, Weisshorn R, Schulte am Esch J: Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility. Eur J Anaesthesiol 2003; 20:528-36
8. Herrmann-Frank A, Richter M, Sarkozi S, Mohr U, Lehmann-Horn F: 4-Chloro-m-cresol, a potent and specific activator of the skeletal muscle ryanodine receptor. Biochim Biophys Acta 1996; 1289:31-40
9. Herrmann-Frank A, Richter M, Lehmann-Horn F: 4-Chloro-m-cresol: A specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle. Biochem Pharmacol 1996; 52:149-55
10. Choisy S, Huchet-Cadiou C, Leoty C: Differential effects of 4-chloro-m-cresol and caffeine on skinned fibers from rat fast and slow skeletal muscles. J Pharmacol Exp Ther 2000; 294:884-93
11. 2+ release by 4-chloro-m-cresol (4-CmC) in intact and chemically skinned ferret cardiac ventricular fibers. J Pharmacol Exp Ther 1999; 290:578-86
12. Struk A, Melzer W: Modification of excitation-contraction coupling by 4-chloro-m-cresol in voltage-clamped cut muscle fibres of the frog (R. pipiens). J Physiol 1999; 515:221-31
13. 2+ release. Mol Pharmacol 1993; 44:1192-201
14. Rosenberg H, Antognini JF, Muldoon S: Testing for malignant hyperthermia. ANESTHESIOLOGY 2002; 96:232-7
15. Weigl L, Ludwig-Pabst C, Kress HG: 4-Chloro-m-cresol cannot detect malignant hyperthermia equivocal cells in an alternative minimally invasive diagnostic test of malignant hyperthermia susceptibility. Anesth Analg 2004; 99:103-7
16. Ducreux S, Zorzato F, Muller C, Sewry C, Muntoni F, Quinlivan R, Restagno G, Girard T, Treves S: Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease. J Biol Chem 2004; 279:43838-46
17. Wehner M, Rueffert H, Koenig F, Olthoff D: Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala. Genet Test 2003; 7:203-11
18. Wehner M, Rueffert H, Koenig F, Meinecke C-D, Olthoff D: The Ile2453Thr mutation in the ryanodine receptor gene 1 is associated with facilitated calcium release from sarcoplasmic reticulum by 4-chloro-m-cresol in human myotubes. Cell Calcium 2003; 34:163-8
19. Wehner M, Rueffert H, Koenig F, Olthoff D: Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model. Neuromuscul Disord 2004; 14:429-37
20. Girard T, Treves S, Censier K, Mueller CR, Zorzato F, Urwyler A: Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells. Br J Anaesth 2002; 89:571-9
21. Girard T, Cavagna D, Padovan E, Spagnoli G, Urwyler A, Zorzato F, Treves S: B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. J Biol Chem 2001; 276:48077-82
22. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, Palmucci LM, Schneider C, Hauser E, Lehmann-Horn F, Muller CR, Treves S: Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: Association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001; 10:2879-87
23. Sei Y, Brandom B, Bina S, Hosoi E, Gallagher KL, Wyre HW, Pudimat PA, Holman SJ, Venzon DJ, Daly JW, Muldoon S: Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes. ANESTHESIOLOGY 2002; 97:1052-8
24. Wehner M, Rueffert H, Koenig F, Neuhaus J, Olthoff D: Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. Clin Genet 2002; 62:135-46
25. Sei Y, Gallagher KL, Basile AS: Skeletal muscle type ryanodine receptor is involved in calcium signaling in human B lymphocytes. J Biol Chem 1999; 274:5995-6002
26. Muschol M, Dasgupta BR, Salzberg BM: Caffeine interaction with fluorescent calcium indicator dyes. Biophys J 1999; 77:577-86
27. Nuccitelli R: A Practical Guide to the Study of Calcium in Living Cells. New York, Academic Press, 1994, pp 155-81
28. Khan AA, Steiner JP, Klein MG, Schneider MF, Snyder SH: IP3 receptor: Localization to plasma membrane of T cells and cocapping with the T cell receptor. Science 1992; 257:815-8
29. Thastrup O, Cullen PJ, Drobak BK, Hanley MR, Dawson AP: Thapsigargin, a tumor promoter, discharges intracellular calcium stores by specific inhibition of the endoplasmic reticulum calcium-ATPase. Proc Nat Acad Sci U S A 1990; 87:2466-70
30. Young HS, Xu C, Zhang P, Stokes DL: Locating the thapsigargin-binding site on Ca(2+)-ATPase by cryoelectron microscopy. J Mol Biol 2001; 308:231-40
31. el-Hayek R, Parness J, Valdivia HH, Coronado R, Hogan K: Dantrolene and azumolene inhibit [3H]PN200-110 binding to porcine skeletal muscle dihydropyridine receptors. Biochem Biophys Res Commun 1992; 187:894-900
32. Sutko JL, Airey JA, Welch W, Ruest L: The pharmacology of ryanodine and related compounds. Pharm Rev 1997; 49:53-98
33. Xu L, Tripathy A, Pasek DA, Meissner G: Potential for pharmacology of ryanodine receptor/calcium release channels. Ann N Y Acad Sci 1998; 853:130-48
34. Laporte R, Hui A, Laher I: Pharmacological modulation of sarcoplasmic reticulum function in smooth muscle. Pharm Rev 2004; 56:439-513
35. 2+ release and influx in human B lymphocytes. Cell Calcium 2001; 29:149-60
36. Lee HC: Mechanisms of calcium signaling by cyclic ADP-ribose and NAADP. Physiol Rev 1997; 77:1133-64
37. Lopez JR, Cordovez G, Linares N, Allen PD: Cyclic ADP-ribose induces a larger than normal calcium release in malignant hyperthermia-susceptible skeletal muscle fibers. Pflugers Arch 2000; 440:236-42
38. Wong L, Aarhus R, Lee HC, Walseth TF: Cyclic 3-deaza-adenosine diphosphoribose: A potent and stable analog of cyclic ADP-ribose. Biochem Biophys Acta 1999; 1472:555-64
39. Franco L, Bruzzone S, Song P, Guida L, Zocchi E, Walseth TF, Crimi E, Usai C, De Flora A, Brusasco V: Extracellular cyclic ADP-ribose potentiates ACh-induced contraction in bovine tracheal smooth muscle. Am J Physiol 2001; 280:L98-106
40. Podesta M, Zocchi E, Pitto A, Usai C, Franco L, Bruzzone S, Guida L, Bacigalupo A, Scadden DT, Walseth TF, De Flora A, Daga A: Extracellular cyclic ADP-ribose increases intracellular free calcium concentration and stimulates proliferation of human hemopoietic progenitors. FASEB J 2000; 14:680-90
41. Klein MG, Simon BJ, Schneider MF: Effects of procaine and caffeine on calcium release from the sarcoplasmic reticulum in frog skeletal muscle. J Physiol 1992; 453:341-66
42. Rhie DJ, Sung JH, Ha US, Kim HJ, Min do S, Hahn SJ, Kim MS, Jo YH, Yoon SH: Endogenous somatostatin receptors mobilize calcium from inositol 1,4,5-trisphosphate-sensitive stores in NG108-15 cells. Brain Res 2003; 975:120-8
43. Ibarra C, Estrada M, Carrasco L, Chiong M, Liberona JL, Cardenas C, Diaz-Araya G, Jaimovich E, Lavandero S: Insulin-like growth factor-1 induces an inositol 1,4,5-trisphosphate-dependent increase in nuclear and cytosolic calcium in cultured rat cardiac myocytes. J Biol Chem 2004; 279:7554-65
44. 2+ entry in vascular endothelial cells is mediated via pathways sensitive to 2-aminoethoxydiphenyl borate and xestospongin C. Br J Pharmacol 2002; 135:119-28
45. Beutner G, Sharma VK, Giovannucci DR, Yule DI, Sheu SS: Identification of a ryanodine receptor in rat heart mitochondria. J Biol Chem 2001; 276:21482-8
46. Fessenden JD, Perez CF, Goth S, Pessah IN, Allen PD: Identification of a key determinant of ryanodine receptor type 1 required for activation by 4-chloro-m-cresol. J Biol Chem 2003; 278:28727-35
47. 2+ release channels: Molecular mechanism and isoform selectivity. J Biol Chem 2001; 276:13810-6
48. Szentesi P, Collet C, Sarkozi S, Szegedi S, Jona I, Jacquemond V, Kovacs L, Csernoch L: Effects of dantrolene on steps of excitation-contraction coupling mammalian skeletal muscle fibers. J Gen Physiol 2001; 118:355-75
49. Anderson K, Cohn AH, Meissner G: High-affinity [3H]PN200-110 and [3H]ryanodine binding to rabbit and frog skeletal muscle. Am J Physiol 1994; 266:C462-6
50. 2+ release channel of sarcoplasmic reticulum from skeletal and cardiac muscle: Evidence for a sequential mechanism in ryanodine action. Mol Pharmacol 1991; 39:679-89
51. 2+ release and influx into smooth muscle cells in response to caffeine: A novel approach for calculating the fraction of current carried by calcium. J Gen Physiol 1994; 104:395-422
52. Guerrero A, Fay FS, Singer JJ: Caffeine activates a Ca(2+)-permeable, nonselective cation channel in smooth muscle cells. J Gen Physiol 1994; 104:375-94
53. Hosoi E, Nishizaki C, Gallagher KL, Wyre HW, Matsuo Y, Sei Y: Expression of the ryanodine receptor isoforms in immune cells. J Immunol 2001; 167:4887-94
54. 2+ current (Icrac) by ryanodine receptors in inositol 1,4,5-trisphosphate-receptor-deficient DT40 cells. Biochem J 2001; 36:17-22
55. Healy JI, Dolmetsch RE, Timmerman LA, Cyster JG, Thomas ML, Crabtree GR, Lewis RS, Goodnow CC: Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity 1997; 6:419-28